IL161832A0 - Pharmaceutical composition for inducing an immune response in a human or animal - Google Patents
Pharmaceutical composition for inducing an immune response in a human or animalInfo
- Publication number
- IL161832A0 IL161832A0 IL16183202A IL16183202A IL161832A0 IL 161832 A0 IL161832 A0 IL 161832A0 IL 16183202 A IL16183202 A IL 16183202A IL 16183202 A IL16183202 A IL 16183202A IL 161832 A0 IL161832 A0 IL 161832A0
- Authority
- IL
- Israel
- Prior art keywords
- inducing
- animal
- human
- immune response
- pharmaceutical composition
- Prior art date
Links
- 241001465754 Metazoa Species 0.000 title abstract 3
- 230000028993 immune response Effects 0.000 title abstract 3
- 230000001939 inductive effect Effects 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 5
- 102000036639 antigens Human genes 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 230000004069 differentiation Effects 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- 210000001550 testis Anatomy 0.000 abstract 2
- 210000004443 dendritic cell Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464486—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200101770 | 2001-11-29 | ||
US33670601P | 2001-12-07 | 2001-12-07 | |
PCT/DK2002/000802 WO2003045427A2 (fr) | 2001-11-29 | 2002-11-29 | Composition pharmaceutique servant a induire une reponse immune chez l'homme ou chez l'animal |
Publications (1)
Publication Number | Publication Date |
---|---|
IL161832A0 true IL161832A0 (en) | 2005-11-20 |
Family
ID=26069102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16183202A IL161832A0 (en) | 2001-11-29 | 2002-11-29 | Pharmaceutical composition for inducing an immune response in a human or animal |
Country Status (12)
Country | Link |
---|---|
US (2) | US7771998B2 (fr) |
EP (1) | EP1448229B1 (fr) |
JP (1) | JP2005515192A (fr) |
AT (1) | ATE446106T1 (fr) |
AU (1) | AU2002365291B2 (fr) |
DE (1) | DE60234115D1 (fr) |
DK (1) | DK1448229T3 (fr) |
ES (1) | ES2335396T3 (fr) |
HK (1) | HK1086750A1 (fr) |
IL (1) | IL161832A0 (fr) |
RU (1) | RU2313365C2 (fr) |
WO (1) | WO2003045427A2 (fr) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPQ755300A0 (en) | 2000-05-17 | 2000-06-08 | Monash University | Immune potentiating compositions |
DE10112851C1 (de) * | 2001-03-16 | 2002-10-10 | Gsf Forschungszentrum Umwelt | Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen |
US6982253B2 (en) | 2002-06-05 | 2006-01-03 | Supergen, Inc. | Liquid formulation of decitabine and use of the same |
DE60316464T2 (de) * | 2002-11-28 | 2008-06-26 | Kufer, Peter, Dr. | Neue real-time rt-pcr methode zur sensitiven detektierung mehrerer mage gen transkripte |
EP1820856B1 (fr) * | 2004-11-18 | 2011-04-27 | National University of Corporation Hiroshima University | Procede et kit destines a exprimer une proteine sous regulation de l'expression a partir d'une sequence repetee formee par une amplification de genes et un transformant |
US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
EP1996614A1 (fr) | 2006-01-30 | 2008-12-03 | The Ludwig Institute for Cancer Research | Antigenes ctsp du cancer du testicule |
GB0612342D0 (en) * | 2006-06-21 | 2006-08-02 | Glaxosmithkline Biolog Sa | Method |
GB0700284D0 (en) * | 2007-01-08 | 2007-02-14 | Glaxosmithkline Biolog Sa | Combination therapy |
EP2154243B1 (fr) * | 2007-05-17 | 2016-01-13 | ID Pharma Co., Ltd. | Procédé de production d'une cellule dendritique |
US20110313229A1 (en) * | 2008-07-24 | 2011-12-22 | Kiminobu Sugaya | Therapy Targeting Cancer Stem Cells |
RU2573912C2 (ru) * | 2008-10-08 | 2016-01-27 | Интрексон Корпорейшн | Сконструированные клетки, экспрессирующие множественные иммуномодуляторы, и их применения |
CN103038343A (zh) * | 2010-03-23 | 2013-04-10 | 英特瑞克斯顿股份有限公司 | 条件表达治疗蛋白的载体,包含所述载体的宿主细胞,及其应用 |
GB201013443D0 (en) * | 2010-08-11 | 2010-09-22 | Cytovac As | Compositions and methods for producing dendritic cells |
CN108635367B (zh) | 2011-08-30 | 2020-08-21 | 阿斯泰克斯制药公司 | 地西他滨衍生物制剂 |
SG10201508535RA (en) * | 2011-10-20 | 2015-11-27 | California Stem Cell Inc | Antigen Presenting Cancer Vaccine |
JP5871228B2 (ja) * | 2011-10-31 | 2016-03-01 | 国立大学法人佐賀大学 | 慢性副鼻腔炎の検出方法 |
GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
DK2812431T3 (da) | 2012-02-09 | 2019-10-14 | Baylor College Medicine | Peptidblandinger til generering af multivirale ctl'er med bred specificitet |
WO2014007669A1 (fr) * | 2012-07-04 | 2014-01-09 | Volgushev Sergei Anatolievich | Vaccin cellulaire autologue pour traiter des affections cancéreuses et procédé de production |
AU2016287585B2 (en) | 2015-07-02 | 2020-12-17 | Otsuka Pharmaceutical Co., Ltd. | Lyophilized pharmaceutical compositions |
SG10202112047TA (en) | 2015-09-18 | 2021-12-30 | Baylor College Medicine | Immunogenic antigen identification from a pathogen and correlation to clinical efficacy |
GB201520542D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
US10519190B2 (en) | 2017-08-03 | 2019-12-31 | Otsuka Pharmaceutical Co., Ltd. | Drug compound and purification methods thereof |
BR112021000620A2 (pt) * | 2018-07-15 | 2021-04-20 | Enochian BioPharma, Inc. | métodos e composições com uso de células dendríticas recombinantes para terapia contra câncer |
EP3903811A1 (fr) | 2020-05-01 | 2021-11-03 | R.G.C.C. Holdings AG | Composition pharmaceutique et procédé pour induire une réponse immunitaire |
EP3981425A1 (fr) | 2020-10-12 | 2022-04-13 | R.G.C.C. Holdings AG | Vaccins anti sras-cov-2 |
CA3119597C (fr) | 2020-10-12 | 2023-07-11 | R.G.C.C. Holdings AG | Vaccins contre le sras-cov-2 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2393738A1 (fr) * | 1999-12-10 | 2001-06-14 | Epimmune Inc. | Induction de reponses immunes cellulaires a her2/neu a l'aide de compositions renfermant des peptides et des acides nucleiques |
US20040241176A1 (en) | 2000-04-27 | 2004-12-02 | Ap Cells. Inc. | Method of producing membrane vesicles |
EP2338507A1 (fr) * | 2001-03-09 | 2011-06-29 | Baylor Research Institute | Procédé de traitement de tumeurs par l'induction de réponses immunitaires du sang |
-
2002
- 2002-11-29 AT AT02803755T patent/ATE446106T1/de not_active IP Right Cessation
- 2002-11-29 JP JP2003546928A patent/JP2005515192A/ja active Pending
- 2002-11-29 EP EP02803755A patent/EP1448229B1/fr not_active Expired - Lifetime
- 2002-11-29 US US10/495,511 patent/US7771998B2/en active Active - Reinstated
- 2002-11-29 DK DK02803755.4T patent/DK1448229T3/da active
- 2002-11-29 ES ES02803755T patent/ES2335396T3/es not_active Expired - Lifetime
- 2002-11-29 DE DE60234115T patent/DE60234115D1/de not_active Expired - Lifetime
- 2002-11-29 AU AU2002365291A patent/AU2002365291B2/en not_active Expired
- 2002-11-29 IL IL16183202A patent/IL161832A0/xx unknown
- 2002-11-29 WO PCT/DK2002/000802 patent/WO2003045427A2/fr active Application Filing
- 2002-11-29 RU RU2004119548/13A patent/RU2313365C2/ru active
-
2006
- 2006-06-16 HK HK06106900.0A patent/HK1086750A1/xx not_active IP Right Cessation
-
2008
- 2008-07-29 US US12/182,089 patent/US7723107B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US20090029457A1 (en) | 2009-01-29 |
RU2004119548A (ru) | 2005-03-27 |
ATE446106T1 (de) | 2009-11-15 |
US7723107B2 (en) | 2010-05-25 |
RU2313365C2 (ru) | 2007-12-27 |
EP1448229B1 (fr) | 2009-10-21 |
US20060051324A1 (en) | 2006-03-09 |
ES2335396T3 (es) | 2010-03-26 |
EP1448229A2 (fr) | 2004-08-25 |
DK1448229T3 (da) | 2010-03-08 |
HK1086750A1 (en) | 2006-09-29 |
AU2002365291B2 (en) | 2007-11-01 |
US7771998B2 (en) | 2010-08-10 |
DE60234115D1 (de) | 2009-12-03 |
AU2002365291A1 (en) | 2003-06-10 |
WO2003045427A2 (fr) | 2003-06-05 |
WO2003045427A3 (fr) | 2004-03-25 |
JP2005515192A (ja) | 2005-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1086750A1 (en) | Pharmaceutical composition for inducing an immune response in a human or animal | |
DE69734605D1 (de) | Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung | |
WO2004091543A3 (fr) | Procede de traitement de maladies auto-immunes en suscitant une presentation d'antigenes par des cellules presentant des antigenes inductrices de tolerance | |
AU7980794A (en) | Methods and compositions for microencapsulation of antigens for use as vaccines | |
HK1033582A1 (en) | Antibodies to death receptor 4 (dr4) and uses thereof | |
IL172700A0 (en) | Compositions and methods for regulating nk cell activity | |
IL172854A0 (en) | Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations | |
NZ306653A (en) | Isolated dna il-17 receptors | |
NZ333607A (en) | Method of stimulating the immune system by transfecting dendritic cells | |
TR199800607T1 (xx) | Dendritik h�cre uyar�c� fakt�r�. | |
IL138424A0 (en) | Covalently reactive antigen analogs and pharmaceutical compositions containing the same | |
WO2002010337A3 (fr) | Methode de clonage de porcs | |
WO2004012681A3 (fr) | Vaccins anticancereux contenant des epitopes d'antigene oncofoetal | |
AU2002223462A1 (en) | Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28 | |
NZ505834A (en) | Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use | |
AU2599002A (en) | Fusion cells and cytokine compositions for treatment of disease | |
WO2002010350A1 (fr) | Technique de proliferation de cellules tueuses naturelles | |
WO2004037198A3 (fr) | Induction de la mort de cellules tumorales provoquee par un anticorps | |
WO2002034287A3 (fr) | Nouvelles formulations de vaccin therapeutique | |
HK1071079A1 (en) | Use of soluble fgl2 as an immunosuppressant | |
MXPA03010261A (es) | Metodos para tratar cancer. | |
Jordan et al. | Role of the NF-κB transcription factor c-Rel in the generation of CD8+ T-cell responses to Toxoplasma gondii | |
ATE412763T1 (de) | Antikörper-abhängige vergrösserung der alphavirus-infektvität | |
WO2004072262A3 (fr) | Cellules presentant l'antigene cd14+ de culture | |
WO2000004918A3 (fr) | Agents utilises en immunotherapie d'affections tumorales |